Pharmaceuticals

Reports on pharmaceuticals findings from University of Texas provide new insights

Published in Clinical Oncology Week, March 29th, 2010

According to recent research from the United States, "Positron emission tomography (PET) and single photon emission computed tomography (SPECT) tracers have been applied to pharmacokinetic, pharmacodynamic, dose-finding, and proof-of-concept studies. PET/SPECT tracers could non-invasively assess treatment endpoints for diseases which used to rely on biopsies and histopathological assays."

"F-18-Fluorodeoxyglucose (FDG) is a gold standard for PET to detect unsuspected distant metastases in cancers. However, F-18-FDG has difficulties in distinguishing between inflammation/infection related masses versus cancer recurrence. Also, tumors with low glycolysis show poor FDG...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Oncology Week

Source: Clinical Oncology Week (2010-03-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry